Anixa Biosciences (NASDAQ:ANIX – Get Free Report) issued its quarterly earnings results on Friday. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02, Zacks reports.
Anixa Biosciences Stock Performance
Shares of Anixa Biosciences stock opened at $2.25 on Friday. The business’s fifty day moving average price is $2.92 and its 200 day moving average price is $3.02. The stock has a market capitalization of $72.40 million, a P/E ratio of -5.77 and a beta of 0.90. Anixa Biosciences has a twelve month low of $2.14 and a twelve month high of $5.13.
Analysts Set New Price Targets
Several equities analysts recently weighed in on ANIX shares. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Anixa Biosciences in a report on Tuesday, November 19th.
About Anixa Biosciences
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Read More
- Five stocks we like better than Anixa Biosciences
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- How to Plot Fibonacci Price Inflection Levels
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.